15 Jan 2015 Posted in News Release By Press Office
Commenting on the report’s publication, Stephen Whitehead, CEO ABPI said:
“I am pleased to see that outcomes for cancer patients in England are slowly improving. This is testament to the hard work of many thousands of professionals dedicated to curing and caring for people with this disease which affects every one of us. It is however disappointing that, in the four years since the House of Commons Committee of Public Accounts reviewed the Department of Health and NHS performance in delivering cancer services, the rate of improvement has been so slow and that older and less well-off patients continue to be disadvantaged.
“Development of new, innovative medicines plays a significant role in improving outcomes for cancer patients and it is shocking to see confirmed, once again, that cancer patients in England are denied the same level of access to these medicines as their European counterparts, meaning thousands of UK patients are missing out on life-enhancing treatment when they need it most. Whilst we may be less likely to develop cancers in this country our chances of survival are reduced, in part due to a lack of access to the right treatments.
“The Cancer Drugs Funds was introduced as a temporary measure to enable the same level of access to medicines for patients as routinely available in the EU. As today’s report points out, we have no evidence that the CDF is working due to a lack of data from which to evaluate its performance, but we can see from patient experience that it has proved nothing more than a sticking plaster having little affect at redressing the balance.
“Now is the time to find a long-term, sustainable solution for evaluating the cost-effectiveness and efficacy of all medicines and we believe that the only solution remains the urgent reform of NICE. We welcome all opportunities to work with NHS and the Department of Health, including through the recently-formed taskforce for cancer services and the Innovative Medicines and MedTech Review, in order support transformation of the health care system so that it enables all patients to access the right medicines at the right time, whatever their condition.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811